Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

CORIXA CORPORATION

UEI: DMZELWDCNKC6

CORIXA CORPORATION is a federal contractor, registered under UEI DMZELWDCNKC6. It has been awarded $37,472,892 across 6 federal contracts. Primary work spans Research and Development in Biotechnology, Research and Development in the Physical, Engineering, and Life Sciences, and Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology). Top awarding agencies include Department Of Health And Human Services and Department Of Defense.

Contact Information

Registration and classification details

Registration

UEI Code

DMZELWDCNKC6

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$31.3M83.4%

Department Of Defense$6.2M16.6%

Awards by NAICS

541711 - Research and Development in Biotechnology$13.7M36.7%

541710 - Research and Development in the Physical, Engineering, and Life Sciences$12.0M32%

541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)$9.0M24.1%

325414 - Biological Product (except Diagnostic) Manufacturing$2.7M7.3%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in CORIXA CORPORATION's top NAICS codes and agencies

TEST KIT, BACTERIA D

Solicitation # SPE2DS-26-T-310W

The contract is for the procurement of 25 units of the API 20 E test kit, designed for the identification of Enterobacteriaceae and other gram-negative rods, under the NSN 6550-01-507-3726. Each purchase group (PG) equals 25 units, and the full order consists of exactly one PG. The product must be delivered within five days of contract award, with delivery terms specified as FOB destination, and no quantity variance is permitted. Strict shelf-life requirements apply: no more than three months may have elapsed from the date of manufacture to the date of delivery, and the item has a non-extendable shelf life of 18 months, classified as a TYPE I CODE K item. The test kits require refrigerated storage between 2 and 8 degrees Celsius at all times. Packaging must comply with commercial standards and Medical Marking Standard No. 1, superseding MIL-STD-129, with each unit sealed in protective containers and shipped in suitable exterior packaging to ensure safe delivery at the lowest freight rate. The product is regulated by the FDA, and the contracting official must submit a referral via EBS for confirmation, including manufacturer and part number details. The manufacturer is bioMérieux Inc with part number 20100. Technical and quality requirements are governed by the DLA Master List, and packaging, marking, and information security controls, including potential covered defense information, are mandated per applicable DLA directives. All documentation and compliance must align with the solicitation SPE2DS-26-T-310W, issued under NAICS code 325414 by the Department of Defense.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

about 6 hours ago

DEADLINE

DDDPlus Software Licensing and SupportThe contract entails the provision of five individual Standard licenses for DDDPlus software, covering full delivery, installation, and compatibility testing to ensure seamless integration with existing systems. License administration will be maintained throughout a four-year term, including ongoing support and compliance management. The work is performance-based with the place of performance located in Silver Spring, Maryland, under a subcontract structure, and falls under the NAICS code 511210 for software publishing. The Department of Health and Human Services is the contracting organization, with a response deadline set for August 14, 2026, and the solicitation was posted on August 4, 2026. All activities must align with federal procurement standards and deliverables must meet technical and operational requirements specified in the agreement.

Department Of Health And Human Services

POSTED

DEADLINE

GastroPlus Software Licensing and SupportThe contract awards the supply and ongoing support of 20 Standard licenses for GastroPlus software over a four-year period, encompassing full delivery, installation, and verification of compatibility with FDA systems. The provider is responsible for ensuring seamless integration into existing infrastructure and managing all aspects of license administration throughout the term. Performance is required to occur at the designated location in Silver Spring, Maryland, with the work falling under NAICS code 511210 for software publishing. The opportunity was posted on August 4, 2026, and responses are due by August 14, 2026, with the contracting entity being the Department of Health and Human Services. This subcontract supports critical regulatory and scientific operations that rely on GastroPlus for pharmacokinetic and pharmacodynamic modeling within federal health and safety contexts.

Department Of Health And Human Services

POSTED

DEADLINE

Custom Multi-Component Veterinary Drug Reference Standards (Sulfonamides)The contract involves the manufacture of two certified lots of multi-component sulfonamide reference standards for veterinary drug applications, each consisting of five 1mL ampules with precisely defined concentration ratios aligned to government-specified tables. The materials must be produced to meet stringent quality and stability requirements, including a minimum shelf life of 12 months at the time of shipment, ensuring long-term usability for regulatory and testing purposes. The standards are designated as ICV and CCV, indicating their use as independent calibration and control verification materials critical to analytical validation and compliance. The work is being procured by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, with performance expected to occur in Denver, Colorado, and classified under NAICS code 325414 for pharmaceutical and botanical product manufacturing. Submission of proposals is due by August 7, 2026, and the contract is structured as a subcontract, suggesting it may follow an overarching government agreement. All output must adhere to exacting specifications to support federal laboratory and inspection protocols, with no flexibility permitted in composition, packaging, or stability validation.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Custom Multi-Component Veterinary Drug Reference Standards (NSAIDs)The contract entails the manufacture and delivery of ISO 17034-certified analytical reference standards specifically for nonsteroidal anti-inflammatory drugs (NSAIDs) to support veterinary drug residue testing. Two certified lots—intermediate control verification (ICV) and candidate control verification (CCV)—will be produced, each containing five 1mL glass ampules sealed for stability and purity. The reference standards are to be dissolved in LC-MS grade solvents to ensure compatibility with high-performance liquid chromatography and mass spectrometry workflows. All materials must meet rigorous certification standards to guarantee accuracy, traceability, and consistency in quantitative analytical applications. The work is required to be completed under a subcontract with a response deadline of August 7, 2026, and the place of performance is designated as Denver, Colorado, with a zip code of 80225. The contracting entity is the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, operating under NAICS code 325414, which corresponds to pharmaceutical preparation manufacturing. The deliverables are critical for laboratory quality control and regulatory compliance in animal health testing, requiring strict adherence to certification protocols and documentation without compromising sample integrity or analytical validity.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Intent to Sole Source - Endotoxin Detection System Cartridges

Solicitation # NOI-CC-OLAO-26-007979

The National Institute of Health, Clinical Center intends to sole source the purchase of proprietary endotoxin detection system cartridges from Charles River Laboratories to support the production and release of PET IND products. These cartridges are essential for bacterial endotoxin testing, ensuring all radiopharmaceuticals are pyrogen-free prior to patient administration, and are compatible only with the institution’s existing portable testing system. Due to the proprietary nature of the cartridges, no alternative suppliers can meet the technical requirements, justifying a sole source acquisition under 41 U.S.C. 253(c)(1) and FAR 6.302-1. The contract requires delivery of cartridges estimated at $22,200 by February 1, 2025, to prevent disruption in patient-ready product release; failure to meet this deadline would compromise the ability to conduct mandatory testing. A separate shipment for additional cartridges is also required by August 24, 2026, to sustain ongoing operations. This is not a request for proposal, but a notice of intent allowing other possible sources to submit capability statements by 12:00 PM Eastern Standard Time on August 7, 2026, to Valerie Gregorio at valerie.gregorio@nih.gov. All submissions received by the deadline will be evaluated, and the government retains full discretion to proceed without competition based on the responses.

National Institutes Of Health

POSTED

DEADLINE

Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription

Solicitation # 7571TE26Q00153

The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.

Department Of Health And Human Services

POSTED

DEADLINE

PEO-M Unmanned Surface Vehicle (USV) Poseidon's Fury Collaboration Event (CE)

Solicitation # PEO_M_USV_Poseidon_s_Fury_CE

SOFWERX and the USSOCOM Program Executive Office Maritime (PEO-M) are hosting the Poseidon’s Fury Collaboration Event to accelerate the development of the Unmanned Surface Vehicle Mission-Aligned Reference Architecture (MARA), a standards-based framework designed to improve interoperability across Joint Force manned and unmanned maritime systems while eliminating redundant, service-specific platform development. This initiative is open exclusively to U.S. persons and involves a two-phase process beginning with a virtual collaboration event on August 26, 2026, where SOF operators and industry partners will engage in breakout sessions to define operational needs around user interface, autonomy, command and control, and platform effectiveness. Participation in this event is optional but strongly encouraged to align solutions with warfighter requirements, with registration closing August 14, 2026. Those who do not attend the CE may still submit capabilities for consideration during the Assessment Event, which opens on September 14, 2026, and closes October 2, 2026. A virtual Q&A session is available on September 23 for clarification on technical expectations. Selected submissions will undergo a downselect process, with winners invited to participate in a comprehensive on-water Assessment Event at Stennis Space Center, Mississippi, between November 2 and 20, 2026. Participants must demonstrate their USV capabilities in real-world conditions, with evaluations conducted by Subject Matter Experts from USSOCOM, JHU APL, WARCOM, and MARSOC using predefined technical and operational criteria. Successful performers may be transitioned to Phase 5, where potential pathways for follow-on acquisition include Other Transaction Authorities (OTAs) under 10 U.S.C. §4022, research agreements under 15 U.S.C. §3715, cooperative R&D agreements, experimental procurement under §4023, or prize competitions—potentially leading to non-competitive production awards based on successful prototype outcomes. All awardees must comply with NIST SP 800-171 for securing Controlled Unclassified Information, and eligibility is limited to U.S. persons and organizations capable of supporting USSOCOM’s unique maritime missions.

Department Of Defense

POSTED

DEADLINE

Request for information - E60PH-28MPIV - Pandemic Influenza Vaccine Readiness and Supply Strategy

Solicitation # WS5703210526

Canada is seeking input from vaccine suppliers to inform its medium- and long-term strategy for ensuring readiness and supply of Pandemic Influenza Vaccine, with a target capacity to produce up to 110 million doses of a monovalent vaccine. This request for information aims to identify potential bidders capable of meeting the government’s needs for rapid, scalable vaccine production in the event of a pandemic, and to better understand industry capabilities, timelines, and conditions for fulfilling future contract opportunities. The initiative is led by the Department of Public Works and Government Services on behalf of the Government of Canada, with responses due by August 7, 2026, and all performance expected to take place within Canada. The NAICS code 325414 indicates the focus is on pharmaceutical and medicine manufacturing, and the sole point of contact for inquiries is Yessica Karnali Wijayaputri of SPAC/PSPC, reachable via email.

Department of Public Works and Government Services

POSTED

DEADLINE

CAM ASSEMBLY, LOWER,

Solicitation # SPE7M4-26-T-299C

The contract pertains to the procurement of a CAM ASSEMBLY, LOWER, identified by part number 74A430615-1001 and NSN 1710-01-478-1569, with a total quantity of 21 units at a unit price of $21.00, resulting in a total contract value of $441.00. Delivery is required within 590 days from the contract award, with FOB origin terms and final inspection and acceptance occurring at the destination. The item is classified as a critical application component, subject to stringent quality verification standards, including zero non-conformances in sampling under MIL-STD-1916 or comparable zero-based plans, with critical, major, and minor attributes assigned specific verification levels or AQLs. Packaging must align with ASTM D3951 and MIL-STD-129 labeling requirements, prioritizing DLA Master List of Technical and Quality Requirements over any conflicting standards, and palletization must comply with RP001 DLA packaging guidelines. The contractor must maintain CMMC Level 2 cybersecurity self-assessment compliance and adhere to all applicable technical and quality references listed in the DLA Master List. The delivery destination is DLA Distribution San Diego at 3581 Cummings Road, Building 3581, San Diego, CA 92136-3581, with a required ship date of June 18, 2026, and an original delivery deadline of February 10, 2029. The solicitation number is SPE7M4-26-T-299C, with a response deadline of August 14, 2026, issued under NAICS code 541712 by the Department of Defense’s Fluid Handling Division, and is managed by point of contact Rory O’Reilly.

FLUID HANDLING DIVISION

POSTED

DEADLINE

In Vitro ADMET AssaysThe contract titled In Vitro ADMET Assays calls for the performance of high-throughput in vitro screening focused on metabolic stability, hepatotoxicity, CYP450 enzyme interactions, and cellular permeability to support early-stage drug development. These assays are critical for evaluating the absorption, distribution, metabolism, excretion, and toxicity profiles of potential therapeutic candidates, enabling informed decisions before advancing compounds into costly clinical stages. The work will be conducted to meet the specific needs of the National Institutes of Health NIDA under the Department of Health and Human Services, with performance expected to occur in Bethesda. This is a subcontract opportunity under NAICS code 541711, which classifies it as research and development in the physical, engineering, and life sciences. The solicitation was posted on August 3, 2026, with a response deadline of August 18, 2026, at 7:00 PM Eastern Time. There is no set-aside classification specified, and no point of contact or detailed office address is provided in the data. Interested parties must submit their proposals before the deadline to be considered for award, with the expectation that the selected contractor will deliver reliable, scalable, and scientifically rigorous ADMET data to guide NIDA’s research initiatives in drug development.

National Institutes Of Health Nida

POSTED

DEADLINE

Genotoxicity and Carcinogenicity TestingThe contract seeks to perform in vitro and in vivo assays to assess the mutagenic and carcinogenic risks of drug candidates, ensuring compliance with regulatory safety standards for pharmaceutical development. The work is critical for identifying potential genetic toxicity and cancer-causing properties early in the drug evaluation process to support regulatory submissions and public health safeguards. The solicitation is issued as a subcontract under the National Institutes of Health NIDA, part of the Department of Health and Human Services, with performance expected to take place in Bethesda. It falls under the NAICS code 541711 for research and development in the physical, engineering, and life sciences. The proposal must be submitted by August 18, 2026, with the opportunity posted on August 3, 2026. No set-aside provisions are specified, and the contract is open to qualified subcontractors with the technical capacity to deliver high-quality genotoxicity and carcinogenicity testing services.

National Institutes Of Health Nida

POSTED

DEADLINE

Safety Pharmacology (CNS, Cardiovascular, Pulmonary)The contract requires comprehensive safety pharmacology studies to evaluate adverse effects on the central nervous system, cardiovascular system, and pulmonary function, ensuring alignment with ICH safety guidelines. The work will involve detailed pharmacodynamic assessments to identify and characterize potential risks to major organ systems during early drug development, with a focus on identifying safety signals that could impact clinical translation. This subcontract, issued by the National Institutes of Health’s NIDA under the Department of Health and Human Services, is set to be performed in Bethesda and has a response deadline of August 18, 2026. The effort is classified under NAICS code 541711, indicating it pertains to research and development in the life sciences, and is aimed at supporting regulatory-compliant preclinical safety evaluations essential for pharmaceutical advancement.

National Institutes Of Health Nida

POSTED

DEADLINE

Toxicity Testing (Acute, Subacute, Subchronic, Chronic)The contract requires the performance of comprehensive toxicity testing in both rodent and non-rodent models to assess organ toxicity and establish safety margins for submission to regulatory authorities as part of an Investigational New Drug application. The scope includes acute, subacute, subchronic, and chronic studies designed to evaluate the potential adverse effects of pharmaceutical compounds across a range of exposure durations and dosages. The work must meet rigorous scientific standards to support regulatory filings and ensure the safety profile of investigational drugs is adequately characterized prior to human trials. This subcontract is issued under the National Institutes of Health, National Institute on Drug Abuse, within the Department of Health and Human Services, with the performance location specified as Bethesda. The North American Industry Classification System code 541711 identifies the work as research and development in the life sciences. The solicitation was posted on August 3, 2026, with a mandatory response deadline of August 18, 2026, at 7:00 PM. No set-aside provisions are specified, and the contract opportunity is open to eligible contractors capable of executing preclinical toxicology studies to support IND submissions.

National Institutes Of Health Nida

POSTED

DEADLINE

In Vivo Pharmacokinetic StudiesThe contract seeks to perform in vivo pharmacokinetic studies to assess the absorption, distribution, metabolism, and excretion of a drug candidate in both rodent and non-rodent species across multiple administration routes, with the goal of generating data to support an Investigational New Drug application. These studies will evaluate drug exposure over time to establish pharmacokinetic profiles critical for regulatory submission, requiring rigorous experimental design, appropriate species selection, and adherence to good laboratory practices. All work must be completed to ensure high-quality, reproducible results that meet FDA expectations for preclinical development. The solicitation is classified as a subcontract under NAICS code 541711, issued by the National Institutes of Health through the National Institute on Drug Abuse, part of the Department of Health and Human Services. Performance is expected to take place in Bethesda, and interested parties must submit their responses no later than August 18, 2026, at 7:00 PM. The opportunity was posted on August 3, 2026, and is open for competitive bidding with no specific set-aside designation. The contract does not provide a point of contact, and all inquiries must be directed through the official SAM.gov portal linked in the posting.

National Institutes Of Health Nida

POSTED

DEADLINE

QuantiFERON®-TB Gold Plus Reagent SupplyThe contract involves the supply of FDA-approved QuantiFERON-TB Gold Plus reagents designed for tuberculosis detection using the DiaSorin LIAISON XL instrument. This subcontract is issued by the Department of Veterans Affairs through the 257-NETWORK Contract Office 17, with performance required in Dallas, Texas, at ZIP code 75216. The reagents must meet stringent regulatory standards and be compatible with the specified diagnostic platform to ensure accurate and reliable results in clinical settings. The solicitation was posted on August 3, 2026, and responses are due by August 10, 2026, at 3:00 PM local time. The NAICS code 325414 identifies this as a business involved in the manufacturing of in vitro diagnostic substances. All reagents must be approved by the FDA and certified for use in tuberculosis screening programs within VA healthcare facilities.

257-NETWORK Contract Office 17 (36C257)

POSTED

DEADLINE

Unable to Decompose Subcontract OpportunitiesDue to a system error, the prime contract details necessary to identify or structure subcontract opportunities could not be retrieved, rendering all subcontracting analysis unavailable at this time. The solicitation is designated as a subcontract under the Department of Health and Human Services, with a posted date of August 3, 2026, and a response deadline of August 18, 2026. The place of performance is listed as Bethesda, Maryland, with a zip code of 20892, though no specific office address, point of contact, or set-aside information is provided. The NAICS code is marked as NA, and the agency and organizational designations are identical, indicating an internal system limitation. Despite the absence of actionable data for suppliers, the opportunity remains live in the system with a public view link available for reference.

Department Of Health And Human Services

POSTED

DEADLINE

Supply of Multi-Level Quality Controls – TRICONTROL

Great Plains Area Indian Health Svc

POSTED

DEADLINE